Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

OXYMIND: Oxytocin-augmented Group Psychotherapy for Patients With Schizophrenia

NCT06136390 is registered in ClinicalTrials.gov with Charite University, Berlin, Germany as lead sponsor.

NCT NCT06136390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06136390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
OXYMIND: Oxytocin-augmented Group Psychotherapy for Patients With Schizophrenia
Lead sponsor
Charite University, Berlin, Germany
Phase
Not applicable
Overall status
Completed
Start date
September 30, 2023
Completion date
December 30, 2024
Enrollment
42 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia spectrum disorders